Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01889 (
ankylosing spondylitis
)
5,717
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recent advances in understanding the mechanism(s) of how IL-6
trans
-signaling regulates immune cell function and promotes inflammation in autoimmune arthritis are critically reviewed. Serum and/or synovial fluid (SF) IL-6 is markedly elevated in adult and juvenile rheumatoid arthritis (RA), psoriatic arthritis (PsA),
ankylosing spondylitis
(AS) and osteoarthritis (OA). IL-6, in concert with IL-17, determines the fate of CD4
+
lymphocytes and therefore TH
17
cell differentiation. IL-6 also plays a critical role in modulating B-lymphocyte activity. The recognition that IL-6
trans
-signaling regulates inflammation resulted in the development of tocilizumab, a fully humanized monoclonal antibody that neutralizes the biological activity of the IL-6-receptor (IL-6R). Significant clinical benefit was demonstrated as well as reduced serum IL-6 levels with suppression of X-ray progression of disease in several clinical trials in which juvenile or adult RA patients were treated with tocilizumab monotherapy or tocilizumab plus methotrexate. However, levels of serum and/or SF IL-6 cytokine protein superfamily members, adiponectin,
oncostatin M
, pre-B-cell colony enhancing factor/visfatin and leukemia inhibitory factor are also elevated in RA. Additional studies will be required to determine if anti-IL-6
trans
-signaling inhibition strategies with tocilizumab or recombinant soluble IL-6R reduce the level of these cytokines.
...
PMID:Recent advances in neutralizing the IL-6 pathway in arthritis. 2778 87
